1 edition of Clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity found in the catalog.
Clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity
Includes bibliographical references.
|Statement||S. O"Meara ... [et al.].|
|Series||Health technology assessment -- 2002 v.6, no.6|
|Contributions||O"Meara, Susan., National Co-ordinating Centre for HTA (Great Britain), Health Technology Assessment Programme.|
|The Physical Object|
|Pagination||iv, 97p. :|
|Number of Pages||97|
Duplicate Title to Long-term cost-effectiveness of weight management in primary care Live Archive, Mr William Nixon - [ Manage ] [ Compare & Merge ] [ Acknowledge ] Background: As obesity prevalence and health-care costs increase, Health Care providers must prevent and manage obesity cost-effectively. clinical outcomes due to their more consistent administration, and suggested that LAIs become a first-line treatment soon after the first episode of schizophrenia (Subotnik et al., ). A recent multi-site, double-blind randomized clinical trial compared the effectiveness of two LAIs, i.e., paliperidone palmitate and haloperidol Size: 2MB.
1 clinical effectiveness and cost of antiviral therapy in pa tients with hepatitis c infection in a managed care setting by chien-ning hsu a dissertation presented to the graduate school of the university of florida in partial fulfillment of the requirements for the degree of doctor of philosophy university of florida Obesity is an increasingly significant U.S. health problem. Over 4 decades, the prevalence of obesity (a body mass index [BMI] 30 kg/m 2) has increased from 13% to 31% in adults and the prevalence of overweight (a BMI of 25 to kg/m 2) has increased from 31% to 34%.Concurrent increases occurred in adolescents and y is especially common in African-American persons, some.
Childhood obesity is one of the most serious problems facing the developed world. It is damaging to the medical and psychological well-being of the child and casts a shadow on their future health, leading to serious illness and ultimately premature ment of Childhood Obesity provides practical, realistic and easily implemented advice on sensitive approaches to children and their Cited by: 4. Cost-effectiveness of primary care referral to a commercial provider for weight loss treatment, relative to standard care: A modelled lifetime analysis. International Journal of Obesity, 38(8),
Treatment of Nature in English Poetry Between Pope and Wordsworth (University of Chicago English studies, no. 3)
Digital Archive - Report upon the Colorado River of the West explored in 1857 and 1858 by Lieutenant Joseph C. Ives, etc., U.S. Geological Survey, Open-File Report 02-25, 2002, (CD-ROM)
Little Brown Bear
architect in practice
Eric Ryan, 1930-1971.
Absconding from Borstals (Research Studies)
Memoir of William Lawrence.
Israel and Babylon
introduction to the chemistry of heterocyclic compounds.
Welfare approaches to the measurement of poverty.
Evaluation of innovative coordination methods utilizing ITS technology for traffic signals
The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity:a technology assessment S O’Meara1* R Riemsma1 L Shirran1 L Mather1 G ter Riet1,2 1 Cited by: Objective: To systematically assess the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
METHODS - SEARCH STRATEGY: Nineteen electronic databases were. The results of the cost-effectiveness analyses suggest that sibutramine 15 mg dominates the other three active interventions and the net benefit analyses show that sibutramine 15 mg is the most cost-effective alternative for thresholds > £ per quality-adjusted life-year (QALY).Cited by: Drug treatments for obesity are licensed for use based on evidence of efficacy obtained from randomized clinical trials, but their effectiveness in routine clinical practice is generally unknown.
In randomized clinical trials orlistat and sibutramine therapy led to reductions in weight varying between weight losses of between 4 and 10 kg over Cited by: The clinical effectiveness and cost effectiveness of sibutramine for obesity.
Technology appraisal guidance [TA31] Published date: 28 October Guidance. This guidance has been replaced by NICE guideline CG Both sibutramine and orlistat have demonstrated effectiveness for obesity treatment and represent evidence-based tools physicians should consider using in appropriate patients.
In the future, using combinations of weight loss medications along with new drugs in development may yield additional safe and long-term treatments to treat this serious Author: Holly Wyatt. Obesity is a multifactorial, chronic disorder that has reached epidemic proportions in most industrialised countries and is threatening to become a global epidemic.
Clinical management of obese patients is complex and serious doubts have arisen with regard to safety and efficacy of drug therapy. Following the withdrawal of fenfluramine and dexfenfluramine ininterest has focused on novel Cited by: The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.
Health Technol Assess ; 6: 1– PubMedCited by: 16 Cost effectiveness of clinical interventions Introduction Methods Cost effectiveness of non-pharmacological interventions Cost effectiveness of sibutramine Cost effectiveness of orlistat Cost effectiveness of surgery 17 Cost effectiveness of public health interventions O'Meara SRiemsma RShirran LMather Lter Riet G The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.
Health Technol Assess. ; 97PubMed Google ScholarCited by: A systematic review of the clinical- and cost- effectiveness of orlistat in the management of obesity showed that a dose of mg three times daily is most effective in terms of weight loss, producing statistically significant differences compared to placebo.
In the current medical literature, we encountered no studies with a comparable study Cited by: Prevention of obesity is often considered a means to reduce this economic burden. Still, information on the cost–effectiveness (CE) and long-term. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity.
Med Decis Making ; Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract ; The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation Health Technol Assess, 13 (), pp.
–, iii–ivCited by: Produced by the Second Panel on Cost-Effectiveness in Health and Medicine--a team of 13 experts from fields including decision science, economics, ethics, psychology, and medicine--this new edition is a comprehensive guide to the use of cost-effectiveness analysis as an evaluative tool at the institutional and policy levels/5(2).
Book Description. This 2 volume set comprises of the 3rd edition of Volume 1 and the 4th edition of Volume 2, both published in In recent years, we’ve developed a much better grasp of the biological and other factors associated with the development of obesity.
Obesity may be the most potent risk factor for incident knee osteoarthritis 21 and is a major cause of Social Security Insurance disability claims. 18 Obesity-associated pulmonary embolism is likely an underreported source of obesity-related death since obesity conferred a relative pulmonary embolism risk of in the Nurses Health Study 22 Cited by: Several studies assessed the cost-effectiveness of sibutramine and orlistat in the treatment of obesity and associated diseases.
These studies have been evaluated in systematic reviews (56,57), indicating that both orlistat and sibutramine appear to be beneficial for the treatment of adults with obesity (56).
Book Description. Several major developments have occurred since the last edition of Handbook of Obesity: Clinical Applications, including new clinical trials, discoveries related to drug use, and greater understanding of the benefits of weight loss in obese in its fourth edition, this volume continues to offer unparalleled depth and breadth of coverage concerning this global and.
Cost effectiveness is estimated to vary between € per life year gained for obese diabetic patients with hypertension and hypercholesterolaemia and €19 per life year gained for obese diabetic patients without other risk factors (Diabetes Care ; ). Handbook of Obesity - Volume 2: Clinical Applications, Fourth Edition - CRC Press Book Several major developments have occurred since the last edition of Handbook of Obesity: Clinical Applications, including new clinical trials, discoveries related to drug use, and greater understanding of the benefits of weight loss in obese patients.What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care?
A systematic review. Health Technol Assess ; 1: ; 21 Bray GA, Ryan DH. Medical Therapy for the Patient with Obesity.
Circulation ; Several major developments have occurred since the last edition of Handbook of Obesity: Clinical Applications, including new clinical trials, discoveries related to drug use, and greater understanding of the benefits of weight loss in obese in its fourth edition, this volume continues to offer unparalleled depth and breadth of coverage concerning this global and chronic disease Price: $